Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment have?
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment has 55 citations in the OpenAlex counts ScholarIQ stores.
When was Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment published?
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment has 2016 year in the ScholarIQ index.
What is the open-access status of Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment?
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment has green oa status in the ScholarIQ index.
What is the DOI of Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment?
The DOI for Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment is on the source record.
What is the PMID of Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment?
The PMID for Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment is on the source record.
What is the OpenAlex record for Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment?
The OpenAlex for Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment is on the source record.